Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

NCT00087009 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Lack of Accrual

Conditions

Leukemia
Lymphoma
Lymphoproliferative Disorder

Interventions

BIOLOGICAL: beta-glucan
BIOLOGICAL: rituximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]